High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.

Adriana C Rossi,Jorge Monge,Ruben Niesvizky,Jingmei Hsu,Tsiporah B. Shore,Koen van Besien,Roger N. Pearse,Tomer M. Mark,David Jayabalan,Sebastian Mayer

High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.

2021

Adriana C Rossi
Jorge Monge
Ruben Niesvizky
Jingmei Hsu
Tsiporah B. Shore
Koen van Besien
Roger N. Pearse
Tomer M. Mark
David Jayabalan
Sebastian Mayer

8021Background: Autologous stem cell transplantation (ASCT) remains a standard of care of eligible patients with multiple myeloma, despite the many novel therapies introduced over the past decade. ...

Keywords:

Internal medicine
Medicine
Melphalan
Lenalidomide
Oncology
standard of care
Refractory Multiple Myeloma
Autologous stem-cell transplantation
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations